CADL
Candel Therapeutics, Inc.
Key Financials
Net Income
$-38182000
↑ 30.8%
Operating Income
$-48266000
↓ 44.6%
Revenue
$125000
0.0%
Total Assets
$125.2M
↑ 17.2%
EPS (Diluted)
$-0.72
↑ 58.6%
Total Liabilities
$73.3M
↑ 80.7%
Shareholders' Equity
$51.9M
↓ 21.7%
Cash & Equivalents
$119.7M
↑ 16.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CADL |
| Company Name | Candel Therapeutics, Inc. |
| CIK | 1841387 |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-916-5445 |